Skip to main content
PMC home page
NeuroRx logoLink to NeuroRx
. 2012 Sep 5;3(3):344–357. doi: 10.1016/j.nurx.2006.05.003

Redox proteomics in some age-related neurodegenerative disorders or models thereof

D Allan Butterfield 1,2,✉, Hafiz Mohmmad Abdul 1,2, Shelley Newman 1,2, Tanea Reed 1,2
PMCID: PMC3593385  PMID: 16815218

Summary

Neurodegenerative diseases cause memory loss and cognitive impairment. Results from basic and clinical scientific research suggest a complex network of mechanisms involved in the process of neurodegeneration. Progress in treatment of such disorders requires researchers to better understand the functions of proteins involved in neurodegenerative diseases, to characterize their role in pathogenic disease mechanisms, and to explore their roles in the diagnosis, treatment, and prevention of neurodegenerative diseases. A variety of conditions of neurodegenerative diseases often lead to post-translational modifications of proteins, including oxidation and nitration, which might be involved in the pathogenesis of neurodegenerative diseases. Redox proteomics, a subset of proteomics, has made possible the identification of specifically oxidized proteins in neurodegenerative disorders, providing insight into a multitude of pathways that govern behavior and cognition and the response of the nervous system to injury and disease. Proteomic analyses are particularly suitable to elucidate post-translational modifications, expression levels, and protein—protein interactions of thousands of proteins at a time. Complementing the valuable information generated through the integrative knowledge of protein expression and function should enable the development of more efficient diagnostic tools and therapeutic modalities. Here we review redox proteomic studies of some neurodegenerative diseases.

Key Words: Redox proteomics, Aβ, (1–42), amyloid beta-peptide, AD, Alzheimer’s disease, mass spectrometry, protein oxidation

References

  • 1.Selkoe DJ. Alzheimer’s disease results from the cerebral accumulation and cytotoxicity of amyloid β-protein. J Alzheimers Dis. 2001;3:75–80. doi: 10.3233/jad-2001-3111. [DOI] [PubMed] [Google Scholar]
  • 2.Cruts M, van Broeckhoven C. Presenilin mutations in Alzheimer’s disease. Hum Mutat. 1998;11:183–190. doi: 10.1002/(SICI)1098-1004(1998)11:3<183::AID-HUMU1>3.0.CO;2-J. [DOI] [PubMed] [Google Scholar]
  • 3.Slooter AJ, Cruts M, Kalmijn S, Hofman A, Breteler MM, van Broeckhoven C, et al. Risk estimates of dementia by apolipoprotein E genotypes from a population-based incidence study: the Rotterdam Study. Arch Neurol. 1998;55:964–968. doi: 10.1001/archneur.55.7.964. [DOI] [PubMed] [Google Scholar]
  • 4.Olanow CW, Tatton WG. Etiology and pathogenesis of Parkinson’s disease. Annu Rev Neurosci. 1999;22:123–144. doi: 10.1146/annurev.neuro.22.1.123. [DOI] [PubMed] [Google Scholar]
  • 5.Gandhi S, Wood NW. Molecular pathogenesis of Parkinson’s disease. Hum Mol Genet. 2005;14:2749–2755. doi: 10.1093/hmg/ddi308. [DOI] [PubMed] [Google Scholar]
  • 6.Kurosinski P, Guggisberg M, Gotz J. Alzheimer’s and Parkinson’s disease: overlapping or synergistic pathologies? Trends Mol Med. 2002;8:3–5. doi: 10.1016/s1471-4914(01)02246-8. [DOI] [PubMed] [Google Scholar]
  • 7.Hensley K, Hall N, Subramaniam R, Cole P, Harris M, Aksenov M, et al. Brain regional correspondence between Alzheimer’s disease histopathology and biomarkers of protein oxidation. J Neurochem. 1995;65:2146–2156. doi: 10.1046/j.1471-4159.1995.65052146.x. [DOI] [PubMed] [Google Scholar]
  • 8.Castegna A, Aksenov M, Aksenova M, Thongboonkerd V, Klein JB, Pierce WM, et al. Proteomic identification of oxidatively modified proteins in Alzheimer’s disease brain. Part I: creatine kinase BB, glutamine synthase, and ubiquitin carboxy-terminal hydrolase L-1. Free Radic Biol Med. 2002;33:562–571. doi: 10.1016/s0891-5849(02)00914-0. [DOI] [PubMed] [Google Scholar]
  • 9.Castegna A, Aksenov M, Thongboonkerd V, Klein JB, Pierce WM, Booze R, et al. Proteomic identification of oxidatively modified proteins in Alzheimer’s disease brain. Part II: dihydropyri-midinase-related protein 2, α-enolase and heat shock cognate 71. J Neurochem. 2002;82:1524–1532. doi: 10.1046/j.1471-4159.2002.01103.x. [DOI] [PubMed] [Google Scholar]
  • 10.Castegna A, Thongboonkerd V, Klein JB, Lynn B, Markesbery WR, Butterfield DA. Proteomic identification of nitrated proteins in Alzheimer’s disease brain. J Neurochem. 2003;85:1394–1401. doi: 10.1046/j.1471-4159.2003.01786.x. [DOI] [PubMed] [Google Scholar]
  • 11.Cleary JP, Walsh DM, Hofmeister JJ, Shankar GM, Kuskowski MA, Selkoe DJ, et al. Natural oligomers of the amyloid-β protein specifically disrupt cognitive function. Nat Neurosci. 2005;8:79–84. doi: 10.1038/nn1372. [DOI] [PubMed] [Google Scholar]
  • 12.Klein WL, Stine WB, Teplow DB. Small assemblies of unmodified amyloid β-protein are the proximate neurotoxin in Alzheimer’s disease. Neurobiol Aging. 2004;25:569–580. doi: 10.1016/j.neurobiolaging.2004.02.010. [DOI] [PubMed] [Google Scholar]
  • 13.Markesbery WR. Oxidative stress hypothesis in Alzheimer’s disease. Free Radic Biol Med. 1997;23:134–147. doi: 10.1016/s0891-5849(96)00629-6. [DOI] [PubMed] [Google Scholar]
  • 14.Boyd-Kimball D, Sultana R, Mohmmad-Abdul H, Butterfield DA. Rodent Aβ(1–42) exhibits oxidative stress properties similar to those of human Aβ(1–42): implications for proposed mechanisms of toxicity. J Alzheimers Dis. 2004;6:515–525. doi: 10.3233/jad-2004-6509. [DOI] [PubMed] [Google Scholar]
  • 15.Sultana R, Ravagna A, Mohmmad-Abdul H, Calabrese V, Butterfield DA. Ferulic acid ethyl ester protects neurons against amyloid β-peptide(1–42)-induced oxidative stress and neurotoxicity: relationship to antioxidant activity. J Neurochem. 2005;92:749–758. doi: 10.1111/j.1471-4159.2004.02899.x. [DOI] [PubMed] [Google Scholar]
  • 16.Drake J, Link CD, Butterfield DA. Oxidative stress precedes fibrillar deposition of Alzheimer’s disease amyloid β-peptide(1–42) in a transgenicCaenorhabditis elegans model. Neurobiol Aging. 2003;24:415–420. doi: 10.1016/s0197-4580(02)00225-7. [DOI] [PubMed] [Google Scholar]
  • 17.Yatin SM, Varadarajan S, Link CD, Butterfield DA. In vitro and in vivo oxidative stress associated with Alzheimer’s amyloid β-peptide(1–42) Neurobiol Aging. 1999;20:325–330. doi: 10.1016/s0197-4580(99)00056-1. [DOI] [PubMed] [Google Scholar]
  • 18.Mohmmad Abdul H, Sultana R, Keller JN, St Clair DK, Markesbery WR, Butterfield DA. Mutations in amyloid precursor protein and presenilin-1 genes increase the basal oxidative stress in murine neuronal cells and lead to increased sensitivity to oxidative stress mediated by amyloid β-pep-tide(1–42), HO and kainic acid: implications for Alzheimer’s disease. J Neurochem. 2006;96:1322–1335. doi: 10.1111/j.1471-4159.2005.03647.x. [DOI] [PubMed] [Google Scholar]
  • 19.Mohmmad Abdul H, Wenk GL, Gramling M, Hauss-Wegrzyniak B, Butterfield DA. APP and PS-1 mutations induce brain oxidative stress independent of dietary cholesterol: implications for Alzheimer’s disease. Neurosci Lett. 2004;368:148–150. doi: 10.1016/j.neulet.2004.06.077. [DOI] [PubMed] [Google Scholar]
  • 20.Boyd-Kimball D, Sultana R, Poon HF, Lynn BC, Casamenti F, Pepeu G, et al. Proteomic identification of proteins specifically oxidized by intracerebral injection of amyloid β-peptide(1–42) into rat brain: implications for Alzheimer’s disease. Neuroscience. 2005;132:313–324. doi: 10.1016/j.neuroscience.2004.12.022. [DOI] [PubMed] [Google Scholar]
  • 21.Lauderback CM, Hackett JM, Huang FF, Keller JN, Szweda LI, Markesbery WR, et al. The glial glutamate transporter, GLT-1, is oxidatively modified by 4-hydroxy-2-nonenal in the Alzheimer’s disease brain: the role of Aβ1–42. J Neurochem. 2001;78:413–416. doi: 10.1046/j.1471-4159.2001.00451.x. [DOI] [PubMed] [Google Scholar]
  • 22.Markesbery WR, Lovell MA. Four-hydroxynonenal, a product of lipid peroxidation, is increased in the brain in Alzheimer’s disease. Neurobiol Aging. 1998;19:33–36. doi: 10.1016/s0197-4580(98)00009-8. [DOI] [PubMed] [Google Scholar]
  • 23.Mariani E, Polidori MC, Cherubini A, Mecocci P. Oxidative stress in brain aging, neurodegenerative and vascular diseases: an overview. J Chromatogr B Analyt Technol Biomed Life Sci. 2005;827:65–75. doi: 10.1016/j.jchromb.2005.04.023. [DOI] [PubMed] [Google Scholar]
  • 24.Butterfield DA, Kanski J. Brain protein oxidation in age-related neurodegenerative disorders that are associated with aggregated proteins. Mech Ageing Dev. 2001;122:945–962. doi: 10.1016/s0047-6374(01)00249-4. [DOI] [PubMed] [Google Scholar]
  • 25.Butterfield DA. Proteomics: a new approach to investigate oxidative stress in Alzheimer’s disease brain. Brain Res. 2004;1000:1–7. doi: 10.1016/j.brainres.2003.12.012. [DOI] [PubMed] [Google Scholar]
  • 26.Choe LH, Dutt MJ, Relkin N, Lee KH. Studies of potential cerebrospinal fluid molecular markers for Alzheimer’s disease. Electrophoresis. 2002;23:2247–2251. doi: 10.1002/1522-2683(200207)23:14<2247::AID-ELPS2247>3.0.CO;2-M. [DOI] [PubMed] [Google Scholar]
  • 27.Rabilloud T. Two-dimensional gel electrophoresis in proteomics: old, old fashioned, but it still climbs up the mountains. Proteomics. 2002;2:3–10. [PubMed] [Google Scholar]
  • 28.Tilleman K, Stevens I, Spittaels K, Haute CV, Clerens S, Van Den Bergh G, et al. Differential expression of brain proteins in glycogen synthase kinase-3 transgenic mice: a proteomics point of view. Proteomics. 2002;2:94–104. [PubMed] [Google Scholar]
  • 29.Smolka MB, Zhou H, Purkayastha S, Aebersold R. Optimization of the isotope-coded affinity tag-labeling procedure for quantitative proteome analysis. Anal Biochem. 2001;297:25–31. doi: 10.1006/abio.2001.5318. [DOI] [PubMed] [Google Scholar]
  • 30.Zhang J, Goodlett DR, Quinn JF, Peskind E, Kaye JA, Zhou Y, et al. Quantitative proteomics of cerebrospinal fluid from patients with Alzheimer’s disease. J Alzheimers Dis. 2005;7:125–133. doi: 10.3233/jad-2005-7205. [DOI] [PubMed] [Google Scholar]
  • 31.Merchant M, Weinberger SR. Recent advancements in surface-enhanced laser desorption/ionization-time of flight-mass spectrometry. Electrophoresis. 2000;21:1164–1177. doi: 10.1002/(SICI)1522-2683(20000401)21:6<1164::AID-ELPS1164>3.0.CO;2-0. [DOI] [PubMed] [Google Scholar]
  • 32.Seibert V, Wiesner A, Buschmann T, Meuer J. Surface-enhanced laser desorption ionization time-of-flight mass spectrometry (SELDI TOF-MS) and ProteinChip technology in proteomics research. Pathol Res Pract. 2004;200:83–94. doi: 10.1016/j.prp.2004.01.010. [DOI] [PubMed] [Google Scholar]
  • 33.Hoogland C, Sanchez JC, Tonella L, Binz PA, Bairoch A, Hochstrasser DF, et al. The 1999 SWISS-2DPAGE database update. Nucleic Acids Res. 2000;28:286–288. doi: 10.1093/nar/28.1.286. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 34.Poon HF, Farr SA, Thongboonkerd V, Lynn BC, Banks WA, Morley JE, et al. Proteomic analysis of specific brain proteins in aged SAMP8 mice treated with α-lipoic acid: implications for aging and age-related neurodegenerative disorders. Neurochem Int. 2005;46:159–168. doi: 10.1016/j.neuint.2004.07.008. [DOI] [PubMed] [Google Scholar]
  • 35.Butterfield DA, Kanski J. Methionine residue 35 is critical for the oxidative stress and neurotoxic properties of Alzheimer’s amyloid β-peptide 1–42. Peptides. 2002;23:1299–1309. doi: 10.1016/s0196-9781(02)00066-9. [DOI] [PubMed] [Google Scholar]
  • 36.Butterfield DA, Lauderback CM. Lipid peroxidation and protein oxidation in Alzheimer’s disease brain: potential causes and consequences involving amyloid β-peptide-associated free radical oxidative stress. Free Radic Biol Med. 2002;32:1050–1060. doi: 10.1016/s0891-5849(02)00794-3. [DOI] [PubMed] [Google Scholar]
  • 37.Smith MA, Richey Harris PL, Sayre LM, Beckman JS, Perry G. Widespread peroxynitrite-mediated damage in Alzheimer’s disease. J Neurosci. 1997;17:2653–2657. doi: 10.1523/JNEUROSCI.17-08-02653.1997. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 38.Lovell MA, Markesbery WR. Ratio of 8-hydroxyguanine in intact DNA to free 8-hydroxyguanine is increased in Alzheimer’s disease ventricular cerebrospinal fluid. Arch Neurol. 2001;58:392–396. doi: 10.1001/archneur.58.3.392. [DOI] [PubMed] [Google Scholar]
  • 39.Varadarajan S, Yatin S, Aksenova M, Butterfield DA. Rew: Alzheimer’s amyloid β-peptide-associated free radical oxidative stress and neurotoxicity. J Struct Biol. 2000;130:184–208. doi: 10.1006/jsbi.2000.4274. [DOI] [PubMed] [Google Scholar]
  • 40.Yatin SM, Varadarajan S, Butterfield DA. Vitamin E prevents Alzheimer’s amyloid β-peptide(1–42)-induced neuronal protein oxidation and reactive oxygen species production. J Alzheimers Dis. 2000;2:123–131. doi: 10.3233/jad-2000-2212. [DOI] [PubMed] [Google Scholar]
  • 41.Butterfield DA, Drake J, Pocemich C, Castegna A. Evidence of oxidative damage in Alzheimer’s disease brain: central role for amyloid β-peptide. Trends Mol Med. 2001;7:548–554. doi: 10.1016/s1471-4914(01)02173-6. [DOI] [PubMed] [Google Scholar]
  • 42.Bollard ME, Stanley EG, Lindon JC, Nicholson JK, Holmes E. NMR-based metabonomic approaches for evaluating physiological influences on biofluid composition. NMR Biomed. 2005;18:143–162. doi: 10.1002/nbm.935. [DOI] [PubMed] [Google Scholar]
  • 43.Sultana R B-KD, Poon HF, Cai J, Pierce WM, Klein JB, et al. Redox proteomics identification of oxidized proteins in Alzheimer’s disease hippocampus and cerebellum: an approach to understand pathological and biochemical alterations in AD.Neurobiol Aging DOI:10.1016/j.neurobiolaging. 2005.05.005 [DOI] [PubMed]
  • 44.Schulz JB, Matthews RT, Beal MF. Role of nitric oxide in neurodegenerative diseases. Curr Opin Neurol. 1995;8:480–486. doi: 10.1097/00019052-199512000-00016. [DOI] [PubMed] [Google Scholar]
  • 45.Keller JN, Schmitt FA, Scheff SW, Ding Q, Chen Q, Butterfield DA, et al. Evidence of increased oxidative damage in subjects with mild cognitive impairment. Neurology. 2005;64:1152–1156. doi: 10.1212/01.WNL.0000156156.13641.BA. [DOI] [PubMed] [Google Scholar]
  • 46.Butterfield DA, Reed T, Perluigi M, De Marco C, Coccia R, Cini C, et al. Elevated protein-bound levels of the lipid peroxidation product, 4-hydroxy-2-nonenal, in brain from persons with mild cognitive impairment. Neurosci Lett. 2006;397:170–173. doi: 10.1016/j.neulet.2005.12.017. [DOI] [PubMed] [Google Scholar]
  • 47.Butterfield DA, Poon HF, St Clair D, Keller JN, Pierce WM, Klein JB, et al. Redox proteomics identification of oxidatively modified hippocampal proteins in mild cognitive impairment: insights into the development of Alzheimer’s disease. Neurobiol Dis. 2006;22:223–232. doi: 10.1016/j.nbd.2005.11.002. [DOI] [PubMed] [Google Scholar]
  • 48.Boyd-Kimball D, Sultana R, Abdul HM, Butterfield DA. γ-glutamylcysteine ethyl ester-induced up-regulation of glutathione protects neurons against Aβ(1–42)-mediated oxidative stress and neurotoxicity: implications for Alzheimer’s disease. J Neurosci Res. 2005;79:700–706. doi: 10.1002/jnr.20394. [DOI] [PubMed] [Google Scholar]
  • 49.Drake J, Kanski J, Varadarajan S, Tsoras M, Butterfield DA. Elevation of brain glutathione by γ-glutamylcysteine ethyl ester protects against peroxynitrite-induced oxidative stress. J Neurosci Res. 2002;68:776–784. doi: 10.1002/jnr.10266. [DOI] [PubMed] [Google Scholar]
  • 50.Butterfield DA, Hensley K, Harris M, Mattson M, Carney J. β-amyloid peptide free radical fragments initiate synaptosomal lipoperoxidation in a sequence-specific fashion: implications to Alzheimer’s disease. Biochem Biophys Res Commun. 1994;200:710–715. doi: 10.1006/bbrc.1994.1508. [DOI] [PubMed] [Google Scholar]
  • 51.Boyd-Kimball D, Castegna A, Sultana R, Poon HF, Petroze R, Lynn BC, et al. Proteomic identification of proteins oxidized by Aβ(1–42) in synaptosomes: implications for Alzheimer’s disease. Brain Res. 2005;1044:206–215. doi: 10.1016/j.brainres.2005.02.086. [DOI] [PubMed] [Google Scholar]
  • 52.Beck KA, Nelson WJ. The spectrin-based membrane skeleton as a membrane protein-sorting machine. Am J Physiol (Lond) 1996;270:C1263–C1270. doi: 10.1152/ajpcell.1996.270.5.C1263. [DOI] [PubMed] [Google Scholar]
  • 53.Masliah E, Mallory M, Hansen L, DeTeresa R, Alford M, Terry R. Synaptic and neuritic alterations during the progression of Alzheimer’s disease. Neurosci Lett. 1994;174:67–72. doi: 10.1016/0304-3940(94)90121-x. [DOI] [PubMed] [Google Scholar]
  • 54.Lubec G, Nonaka M, Krapfenbauer K, Gratzer M, Cairns N, Fountoulakis M. Expression of the dihydropyrimidinase related protein 2 (DRP-2) in Down syndrome and Alzheimer’s disease brain is downregulated at the mRNA and dysregulated at the protein level. J Neural Transm Suppl. 1999;57:161–177. doi: 10.1007/978-3-7091-6380-1_10. [DOI] [PubMed] [Google Scholar]
  • 55.Coleman PD, Flood DG. Neuron numbers and dendritic extent in normal aging and Alzheimer’s disease. Neurobiol Aging. 1987;8:521–545. doi: 10.1016/0197-4580(87)90127-8. [DOI] [PubMed] [Google Scholar]
  • 56.Aksenov MY, Aksenova MV, Butterfield DA, Geddes JW, Markesbery WR. Protein oxidation in the brain in Alzheimer’s disease. Neuroscience. 2001;103:373–383. doi: 10.1016/s0306-4522(00)00580-7. [DOI] [PubMed] [Google Scholar]
  • 57.Lauderback CM, Kanski J, Hackett JM, Maeda N, Kindy MS, Butterfield DA. Apolipoprotein E modulates Alzheimer’s Aβ(1–42)-induced oxidative damage to synaptosomes in an allele-specific manner. Brain Res. 2002;924:90–97. doi: 10.1016/s0006-8993(01)03228-0. [DOI] [PubMed] [Google Scholar]
  • 58.Subramaniam R, Roediger F, Jordan B, Mattson MP, Keller JN, Waeg G, et al. The lipid peroxidation product, 4-hydroxy-2-transnonenal, alters the conformation of cortical synaptosomal membrane proteins. J Neurochem. 1997;69:1161–1169. doi: 10.1046/j.1471-4159.1997.69031161.x. [DOI] [PubMed] [Google Scholar]
  • 59.Hamos JE, DeGennaro LJ, Drachman DA. Synaptic loss in Alzheimer’s disease and other dementias. Neurology. 1989;39:355–361. doi: 10.1212/wnl.39.3.355. [DOI] [PubMed] [Google Scholar]
  • 60.Harkany T, O’Mahony S, Keijser J, Kelly JP, Konya C, Borostyankoi ZA, et al. β-amyloid(1–42)-induced cholinergic lesions in rat nucleus basalis bidirectionally modulate serotonergic innervation of the basal forebrain and cerebral cortex. Neurobiol Dis. 2001;8:667–678. doi: 10.1006/nbdi.2001.0398. [DOI] [PubMed] [Google Scholar]
  • 61.Dougherty MK, Morrison DK. Unlocking the code of 14-3-3. J Cell Sci. 2004;117:1875–1884. doi: 10.1242/jcs.01171. [DOI] [PubMed] [Google Scholar]
  • 62.Takahashi Y. The 14-3-3 proteins: gene, gene expression, and function. Neurochem Res. 2003;28:1265–1273. doi: 10.1023/a:1024296932670. [DOI] [PubMed] [Google Scholar]
  • 63.Vanhanen M, Soininen H. Glucose intolerance, cognitive impairment and Alzheimer’s disease. Curr Opin Neurol. 1998;11:673–677. doi: 10.1097/00019052-199812000-00011. [DOI] [PubMed] [Google Scholar]
  • 64.Scheltens P, Korf ES. Contribution of neuroimaging in the diagnosis of Alzheimer’s disease and other dementias. Curr Opin Neurol. 2000;13:391–396. doi: 10.1097/00019052-200008000-00005. [DOI] [PubMed] [Google Scholar]
  • 65.Messier C, Gagnon M. Glucose regulation and brain aging. J Nutr Health Aging. 2000;4:208–213. [PubMed] [Google Scholar]
  • 66.Iwangoff P, Armbruster R, Enz A, Meier-Ruge W. Glycolytic enzymes from human autoptic brain cortex: normal aged and demented cases. Mech Ageing Dev. 1980;14:203–209. doi: 10.1016/0047-6374(80)90120-7. [DOI] [PubMed] [Google Scholar]
  • 67.Ogawa M, Fukuyama H, Ouchi Y, Yamauchi H, Kimura J. Altered energy metabolism in Alzheimer’s disease. J Neurol Sci. 1996;139:78–82. [PubMed] [Google Scholar]
  • 68.Casamenti F, Prosperi C, Scali C, Giovannelli L, Colivicchi MA, Faussone-Pellegrini MS, et al. Interleukin-1β activates forebrain glial cells and increases nitric oxide production and cortical glutamate and GABA release in vivo: implications for Alzheimer’s disease. Neuroscience. 1999;91:831–842. doi: 10.1016/s0306-4522(98)00680-0. [DOI] [PubMed] [Google Scholar]
  • 69.Li JY, Henning Jensen P, Dahlstrom A. Differential localization of α-,β- and γ-synucleins in the rat CNS. Neuroscience. 2002;113:463–478. doi: 10.1016/s0306-4522(02)00143-4. [DOI] [PubMed] [Google Scholar]
  • 70.Frolich L. The cholinergic pathology in Alzheimer’s disease: discrepancies between clinical experience and pathophysiological findings. J Neural Transm. 2002;109:1003–1013. doi: 10.1007/s007020200083. [DOI] [PubMed] [Google Scholar]
  • 71.Giovannini MG, Scali C, Prosperi C, Bellucci A, Vannucchi MG, Rosi S, et al. β-amyloid-induced inflammation and cholinergic hypofunction in the rat brain in vivo: involvement of the p38MAPK pathway. Neurobiol Dis. 2002;11:257–274. doi: 10.1006/nbdi.2002.0538. [DOI] [PubMed] [Google Scholar]
  • 72.Bozner P, Wilson GL, Druzhyna NM, Bryant-Thomas TK, Le-Doux SP, et al. Deficiency of chaperonin 60 in Down’s syndrome. J Alzheimers Dis. 2002;4:479–486. doi: 10.3233/jad-2002-4604. [DOI] [PubMed] [Google Scholar]
  • 73.Lin KM, Lin B, Lian IY, Mestril R, Scheffler IE, Dillmann WH. Combined and individual mitochondrial HSP60 and HSP10 expression in cardiac myocytes protects mitochondrial function and prevents apoptotic cell deaths induced by simulated ischemia-reoxygenation. Circulation. 2001;103:1787–1792. doi: 10.1161/01.cir.103.13.1787. [DOI] [PubMed] [Google Scholar]
  • 74.Boyd-Kimball DPH, Lynn BC, Cai J, Pierce WM Jr, Klein JB, et al. Proteomic identification of proteins specifically oxidized inCaenorhabditis elegans expressing human Aβ(1–42): implications for Alzheimer’s disease.Neurobiol Aging DOI:10.1016/ j.neurobiolaging. 2005.07.001 [DOI] [PubMed]
  • 75.Castegna A, Thongboonkerd V, Klein J, Lynn BC, Wang YL, Osaka H, et al. Proteomic analysis of brain proteins in the gracile axonal dystrophy (gad) mouse, a syndrome that emanates from dysfunctional ubiquitin carboxyl-terminal hydrolase L-1, reveals oxidation of key proteins. J Neurochem. 2004;88:1540–1546. doi: 10.1046/j.1471-4159.2003.02288.x. [DOI] [PubMed] [Google Scholar]
  • 76.Elder GA, Friedrich VL, Lazzarini RA. Schwann cells and oligodendrocytes read distinct signals in establishing myelin sheath thickness. J Neurosci Res. 2001;65:493–499. doi: 10.1002/jnr.1179. [DOI] [PubMed] [Google Scholar]
  • 77.Beckman JS. Oxidative damage and tyrosine nitration from peroxynitrite. Chem Res Toxicol. 1996;9:836–844. doi: 10.1021/tx9501445. [DOI] [PubMed] [Google Scholar]
  • 78.Chou SM, Wang HS, Taniguchi A, Bucala R. Advanced glycation endproducts in neurofilament conglomeration of motoneurons in familial and sporadic amyotrophic lateral sclerosis. Mol Med. 1998;4:324–332. [PMC free article] [PubMed] [Google Scholar]
  • 79.Cookson MR, Shaw PJ. Oxidative stress and motor neurone disease. Brain Pathol. 1999;9:165–186. doi: 10.1111/j.1750-3639.1999.tb00217.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 80.Butterfield DA, Howard BJ, Yatin S, Allen KL, Carney JM. Free radical oxidation of brain proteins in accelerated senescence and its modulation by N-tert-butyl-α-phenylnitrone. Proc Natl Acad Sci USA. 1997;94:674–678. doi: 10.1073/pnas.94.2.674. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 81.Butterfield DA, Castegna A. Proteomics for the identification of specifically oxidized proteins in brain: technology and application to the study of neurodegenerative disorders. Amino Acids. 2003;25:419–425. doi: 10.1007/s00726-003-0027-7. [DOI] [PubMed] [Google Scholar]
  • 82.Takeda T, Hosokawa M, Takeshita S, Irino M, Higuchi K, Matsushita T, et al. A new murine model of accelerated senescence. Mech Aging Dev. 1981;17:183–194. doi: 10.1016/0047-6374(81)90084-1. [DOI] [PubMed] [Google Scholar]
  • 83.Chen GH, Wang YJ, Wang XM, Zhou JN, Liu RY. Effect of aging on species-typical behaviors in senescence-accelerated mouse. Physiol Behav. 2005;85:536–545. doi: 10.1016/j.physbeh.2005.06.002. [DOI] [PubMed] [Google Scholar]
  • 84.Flood JF, Morley JE. Learning and memory in the SAMP8 mouse. Neurosci Biobehav Rev. 1998;22:1–20. doi: 10.1016/s0149-7634(96)00063-2. [DOI] [PubMed] [Google Scholar]
  • 85.Butterfield DA, Poon HF. The senescence-accelerated prone mouse (SAMP8): a model of age-related cognitive decline with relevance to alterations of the gene expression and protein abnormalities in Alzheimer’s disease. Exp Gerontol. 2005;40:774–783. doi: 10.1016/j.exger.2005.05.007. [DOI] [PubMed] [Google Scholar]
  • 86.Farr SA, Poon HF, Dogrukol-Ak D, Drake J, Banks WA, Eyerman E, et al. The antioxidants α-lipoic acid and N-acetylcysteine reverse memory impairment and brain oxidative stress in aged SAMP8 mice. J Neurochem. 2003;84:1173–1183. doi: 10.1046/j.1471-4159.2003.01580.x. [DOI] [PubMed] [Google Scholar]
  • 87.Poon HF, Castegna A, Farr SA, Thongboonkerd V, Lynn BC, Banks WA, et al. Quantitative proteomics analysis of specific protein expression and oxidative modification in aged senescence-accelerated-prone 8 mice brain. Neuroscience. 2004;126:915–926. doi: 10.1016/j.neuroscience.2004.04.046. [DOI] [PubMed] [Google Scholar]
  • 88.Kawamata T, Akiguchi I, Maeda K, Tanaka C, Higuchi K, Hosokawa M, et al. Age-related changes in the brains of senescence-accelerated mice (SAM): association with glial and endothelial reactions. Microsc Res Tech. 1998;43:59–67. doi: 10.1002/(SICI)1097-0029(19981001)43:1<59::AID-JEMT9>3.0.CO;2-X. [DOI] [PubMed] [Google Scholar]
  • 89.Shimano Y. [Studies on aging through analysis of the glucose metabolism related to the ATP-production of the senescence accelerated mouse (SAM)] Hokkaido Igaku Zasshi. 1998;73:557–569. [PubMed] [Google Scholar]
  • 90.Packer L, Roy S, Sen CK. α-lipoic acid: a metabolic antioxidant and potential redox modulator of transcription. Adv Pharmacol. 1997;38:79–101. doi: 10.1016/s1054-3589(08)60980-1. [DOI] [PubMed] [Google Scholar]
  • 91.Packer L, Tritschler HJ, Wessel K. Neuroprotection by the metabolic antioxidant α-lipoic acid. Free Radic Biol Med. 1997;22:359–378. doi: 10.1016/s0891-5849(96)00269-9. [DOI] [PubMed] [Google Scholar]
  • 92.Kagan VE, Shvedova A, Serbinova E, Khan S, Swanson C, Powell R, et al. Dihydrolipoic acid-a universal antioxidant both in the membrane and in the aqueous phase: reduction of peroxyl, ascorbyl and chromanoxyl radicals. Biochem Pharmacol. 1992;44:1637–1649. doi: 10.1016/0006-2952(92)90482-x. [DOI] [PubMed] [Google Scholar]
  • 93.Ou P, Tritschler HJ, Wolff SP. Thioctic (lipoic) acid: a therapeutic metal-chelating antioxidant? Biochem Pharmacol. 1995;50:123–126. doi: 10.1016/0006-2952(95)00116-h. [DOI] [PubMed] [Google Scholar]
  • 94.Sen CK, Roy S, Han D, Packer L. Regulation of cellular thiols in human lymphocytes by α-lipoic acid: a flow cytometric analysis. Free Radie Biol Med. 1997;22:1241–1257. doi: 10.1016/s0891-5849(96)00552-7. [DOI] [PubMed] [Google Scholar]
  • 95.Melone MA, Jori FP, Peluso G. Huntington’s disease: new frontiers for molecular and cell therapy. Curr Drug Targets. 2005;6:43–56. doi: 10.2174/1389450053344975. [DOI] [PubMed] [Google Scholar]
  • 96.Muchowski PJ, Wacker JL. Modulation of neurodegeneration by molecular chaperones. Nat Rev Neurosci. 2005;6:11–22. doi: 10.1038/nrn1587. [DOI] [PubMed] [Google Scholar]
  • 97.Kumar VB, Vyas K, Franko M, Choudhary V, Buddhiraju C, Alvarez J, et al. Molecular cloning, expression, and regulation of hippocampal amyloid precursor protein of senescence accelerated mouse (SAMP8) Biochem Cell Biol. 2001;79:57–67. [PubMed] [Google Scholar]
  • 98.Poon HF, Joshi G, Sultana R, Farr SA, Banks WA, Morley JE, et al. Antisense directed at the Aβ region of APP decreases brain oxidative markers in aged senescence accelerated mice. Brain Res. 2004;1018:86–96. doi: 10.1016/j.brainres.2004.05.048. [DOI] [PubMed] [Google Scholar]
  • 99.Bulliard C, Zurbriggen R, Tornare J, Faty M, Dastoor Z, Dreyer JL. Purification of a dichlorophenol-indophenol oxidoreductase from rat and bovine synaptic membranes: tight complex association of a glyceraldehyde-3-phosphate dehydrogenase isoform, TOAD64, enolase-γ and aldolase C. Biochem J. 1997;324:555–563. doi: 10.1042/bj3240555. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 100.de Hostos EL, Bradtke B, Lottspeich F, Guggenheim R, Gerisch G. Coronin, an actin binding protein ofDictyostelium discoideum localized to cell surface projections, has sequence similarities to G proteinβ subunits. EMBO J. 1991;10:4097–4104. doi: 10.1002/j.1460-2075.1991.tb04986.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 101.Sarafian TA, Verity MA, Vinters HV, Shih CC, Shi L, Ji XD, et al. Differential expression of peroxiredoxin subtypes in human brain cell types. J Neurosci Res. 1999;56:206–212. [PubMed] [Google Scholar]
  • 102.Kim H, Lee TH, Park ES, Suh JM, Park SJ, Chung HK, et al. Role of peroxiredoxins in regulating intracellular hydrogen peroxide and hydrogen peroxide-induced apoptosis in thyroid cells. J Biol Chem. 2000;275:18266–18270. doi: 10.1074/jbc.275.24.18266. [DOI] [PubMed] [Google Scholar]
  • 103.Butterfield D, Castegna A, Pocemich C, Drake J, Scapagnini G, Calabrese V. Nutritional approaches to combat oxidative stress in Alzheimer’s disease. J Nutr Biochem. 2002;13:444–444. doi: 10.1016/s0955-2863(02)00205-x. [DOI] [PubMed] [Google Scholar]
  • 104.Kirby J, Halligan E, Baptista MJ, Allen S, Heath PR, Holden H, et al. Mutant SOD1 alters the motor neuronal transcriptome: implications for familial ALS. Brain. 2005;128:1686–1706. doi: 10.1093/brain/awh503. [DOI] [PubMed] [Google Scholar]
  • 105.Andersen PM. Genetic factors in the early diagnosis of ALS. Amyotroph Lateral Scler Other Motor Neuron Disord. 2000;1:S31–S42. doi: 10.1080/14660820052415899. [DOI] [PubMed] [Google Scholar]
  • 106.Gumey ME. Transgenic animal models of familial amyotrophic lateral sclerosis. J Neurol. 1997;244:S15–S20. doi: 10.1007/BF03160575. [DOI] [PubMed] [Google Scholar]
  • 107.Poon HF, Hensley K, Thongboonkerd V, Merchant ML, Lynn BC, Pierce WM, et al. Redox proteomics analysis of oxidatively modified proteins in G93A-SOD1 transgenic mice: a model of familial amyotrophic lateral sclerosis. Free Radic Biol Med. 2005;39:453–462. doi: 10.1016/j.freeradbiomed.2005.03.030. [DOI] [PubMed] [Google Scholar]
  • 108.Andrus PK, Fleck TJ, Gumey ME, Hall ED. Protein oxidative damage in a transgenic mouse model of familial amyotrophic lateral sclerosis. J Neurochem. 1998;71:2041–2048. doi: 10.1046/j.1471-4159.1998.71052041.x. [DOI] [PubMed] [Google Scholar]
  • 109.Curti D, Malaspina A, Facchetti G, Camana C, Mazzini L, Tosca P, et al. Amyotrophic lateral sclerosis: oxidative energy metabolism and calcium homeostasis in peripheral blood lymphocytes. Neurology. 1996;47:1060–1064. doi: 10.1212/wnl.47.4.1060. [DOI] [PubMed] [Google Scholar]
  • 110.Bergmann F, Keller BU. Impact of mitochondrial inhibition on excitability and cytosolic Ca2+ levels in brainstem motoneurones from mouse. J Physiol (Lond) 2004;555:45–59. doi: 10.1113/jphysiol.2003.053900. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 111.Vigouroux S, Briand M, Briand Y. Linkage between the protea-some pathway and neurodegenerative diseases and aging. Mol Neurobiol. 2004;30:201–221. doi: 10.1385/MN:30:2:201. [DOI] [PubMed] [Google Scholar]
  • 112.Ganea E. Chaperone-like activity of α-crystalline and other small heat shock proteins. Curr Protein Pept Sci. 2001;2:205–225. doi: 10.2174/1389203013381107. [DOI] [PubMed] [Google Scholar]
  • 113.Perluigi M, Fai Poon H, Hensley K, Pierce WM, Klein JB, Calabrese V, et al. Proteomic analysis of 4-hydroxy-2-nonenal-modified proteins in G93A-SOD1 transgenic mice: a model of familial amyotrophic lateral sclerosis. Free Radic Biol Med. 2005;38:960–968. doi: 10.1016/j.freeradbiomed.2004.12.021. [DOI] [PubMed] [Google Scholar]
  • 114.Kieran D, Kalmar B, Dick JR, Riddoch-Contreras J, Burnstock G, Greensmith L. Treatment with arimoclomol, a coinducer of heat shock proteins, delays disease progression in ALS mice. Nat Med. 2004;10:402–405. doi: 10.1038/nm1021. [DOI] [PubMed] [Google Scholar]
  • 115.Zhang J, Goodlett DR. Proteomic approach to studying Parkinson’s disease. Mol Neurobiol. 2004;29:271–288. doi: 10.1385/MN:29:3:271. [DOI] [PubMed] [Google Scholar]
  • 116.Recchia A, Debetto P, Negro A, Guidolin D, Skaper SD, Giusti P. α-synuclein and Parkinson’s disease. FASEB J. 2004;18:617–626. doi: 10.1096/fj.03-0338rev. [DOI] [PubMed] [Google Scholar]
  • 117.Cabin DE, Shimazu K, Murphy D, Cole NB, Gottschalk W, McIlwain KL, et al. Synaptic vesicle depletion correlates with attenuated synaptic responses to prolonged repetitive stimulation in mice lacking α-synuclein. J Neurosci. 2002;22:8797–8807. doi: 10.1523/JNEUROSCI.22-20-08797.2002. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 118.Kruger R, Kuhn W, Muller T, Woitalla D, Graeber M, Kosel S, et al. Ala30Pro mutation in the gene encoding α-synuclein in Parkinson’s disease. Nat Genet. 1998;18:106–108. doi: 10.1038/ng0298-106. [DOI] [PubMed] [Google Scholar]
  • 119.De Iuliis A, Grigoletto J, Recchia A, Giusti P, Arslan P. A proteomic approach in the study of an animal model of Parkinson’s disease. Clin Chim Acta. 2005;357:202–209. doi: 10.1016/j.cccn.2005.03.028. [DOI] [PubMed] [Google Scholar]
  • 120.Aksenov MY, Tucker HM, Nair P, Aksenova MV, Butterfield DA, Estus S, et al. The expression of key oxidative stress-handling genes in different brain regions in Alzheimer’s disease. J Mol Neurosci. 1998;11:151–164. doi: 10.1385/JMN:11:2:151. [DOI] [PubMed] [Google Scholar]
  • 121.Ardley HC, Scott GB, Rose SA, Tan NG, Robinson PA. UCH-L1 aggresome formation in response to proteasome impairment indicates a role in inclusion formation in Parkinson’s disease. J Neurochem. 2004;90:379–391. doi: 10.1111/j.1471-4159.2004.02485.x. [DOI] [PubMed] [Google Scholar]
  • 122.Canet-Aviles RM, Wilson MA, Miller DW, Ahmad R, McLendon C, Bandyopadhyay S, et al. The Parkinson’s disease protein DJ-1 is neuroprotective due to cysteine-sulfinic acid-driven mitochondrial localization. Proc Natl Acad Sci USA. 2004;101:9103–9108. doi: 10.1073/pnas.0402959101. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 123.Valente EM, Abou-Sleiman PM, Caputo V, Muqit MM, Harvey K, Gispert S, et al. Hereditary early-onset Parkinson’s disease caused by mutations in PINK1. Science. 2004;304:1158–1160. doi: 10.1126/science.1096284. [DOI] [PubMed] [Google Scholar]
  • 124.von Coelln R, Dawson VL, Dawson TM. Parkin-associated Parkinson’s disease. Cell Tissue Res. 2004;318:175–184. doi: 10.1007/s00441-004-0924-4. [DOI] [PubMed] [Google Scholar]
  • 125.Junn E, Mouradian MM. Human α-synuclein over-expression increases intracellular reactive oxygen species levels and susceptibility to dopamine. Neurosci Lett. 2002;320:146–150. doi: 10.1016/s0304-3940(02)00016-2. [DOI] [PubMed] [Google Scholar]
  • 126.Poon HF, Frasier M, Shreve N, Calabrese V, Wolozin B, Butterfield DA. Mitochondrial associated metabolic proteins are selectively oxidized in A30P α-synuclein transgenic mice: a model of familial Parkinson’s disease. Neurobiol Dis. 2005;18:492–498. doi: 10.1016/j.nbd.2004.12.009. [DOI] [PubMed] [Google Scholar]
  • 127.Kremer B, Weber B, Hayden MR. New insights into the clinical features, pathogenesis and molecular genetics of Huntington’s disease. Brain Pathol. 1992;2:321–335. doi: 10.1111/j.1750-3639.1992.tb00709.x. [DOI] [PubMed] [Google Scholar]
  • 128.Leavitt BR, Wellington CL, Hayden MR. Recent insights into the molecular pathogenesis of Huntington’s disease. Semin Neurol. 1999;19:385–395. doi: 10.1055/s-2008-1040853. [DOI] [PubMed] [Google Scholar]
  • 129.Burke JR, Enghild JJ, Martin ME, Jou YS, Myers RM, Roses AD, et al. Huntington and DRPLA proteins selectively interact with the enzyme GAPDH. Nat Med. 1996;2:347–350. doi: 10.1038/nm0396-347. [DOI] [PubMed] [Google Scholar]
  • 130.Saunders PA, Chen RW, Chuang DM. Nuclear translocation of glyceraldehyde-3-phosphate dehydrogenase isoforms during neuronal apoptosis. J Neurochem. 1999;72:925–932. doi: 10.1046/j.1471-4159.1999.0720925.x. [DOI] [PubMed] [Google Scholar]
  • 131.Sawa A, Khan AA, Hester LD, Snyder SH. Glyceraldehyde-3-phosphate dehydrogenase: nuclear translocation participates in neuronal and nonneuronal cell death. Proc Natl Acad Sci USA. 1997;94:11669–11674. doi: 10.1073/pnas.94.21.11669. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 132.Calabresi P, Gubellini P, Picconi B, Centonze D, Pisani A, Bonsi P, et al. Inhibition of mitochondrial complex II induces a long-term potentiation of NMDA-mediated synaptic excitation in the striatum requiring endogenous dopamine. J Neurosci. 2001;21:5110–5120. doi: 10.1523/JNEUROSCI.21-14-05110.2001. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 133.LaFontaine MA, Geddes JW, Butterfield DA. 3-Nitropropionic acid-induced changes in bilayer fluidity in synaptosomal membranes: implications for Huntington’s disease. Neurochem Res. 2002;27:507–511. doi: 10.1023/a:1019852720521. [DOI] [PubMed] [Google Scholar]
  • 134.Fontaine MA, Geddes JW, Banks A, Butterfield DA. Effect of exogenous and endogenous antioxidants on 3-nitropionic acid-induced in vivo oxidative stress and striatal lesions: insights into Huntington’s disease. J Neurochem. 2000;75:1709–1715. doi: 10.1046/j.1471-4159.2000.0751709.x. [DOI] [PubMed] [Google Scholar]
  • 135.Perluigi M, Poon HF, Maragos W, Pierce WM, Klein JB, Calabrese V, et al. Proteomic analysis of protein expression and oxidative modification in r6/2 transgenic mice: a model of Huntington’s disease. Mol Cell Proteomics. 2005;4:1849–1861. doi: 10.1074/mcp.M500090-MCP200. [DOI] [PubMed] [Google Scholar]
  • 136.Sultana RPH, Cai J, Pierce WM, Merchant M, Klein JB, et al. Identification of nitrated proteins in Alzheimer’s disease brain using a redox proteomics approach.Neurobiol Dis DOI:10.1016/ j.neurobiolaging. 2005.05.005 [DOI] [PubMed]
  • 137.Vis JC, de Boer-van Huizen RT, Verbeek MM, de Waal RM, ten Donkelaar HJ, Kremer B. Creatine protects against 3-nitropropionic acid-induced cell death in murine corticostriatal slice cultures. Brain Res. 2004;1024:16–24. doi: 10.1016/j.brainres.2004.06.087. [DOI] [PubMed] [Google Scholar]

Articles from NeuroRx are provided here courtesy of Am. Soc. for Experimental NeuroTherapeutics

RESOURCES